Natco Pharma Challenges Novo Nordisk's Semaglutide Patent in Delhi HC

Natco Pharma, an Indian drug company, has asked the Delhi High Court to cancel Novo Nordisk's patent for a diabetes medicine called semaglutide.

This medicine is also used for weight loss and is sold as Ozempic.

The patent is set to expire in March 2026.

The court will hear the case on February 5.

Earlier, Dr Reddy’s Laboratories also challenged the same patent.

Novo Nordisk has patents in India for the medicine and how it is given to patients.

The basic patent for the medicine itself expired in 2024.

Natco Pharma and its partner Mylan have settled a similar case in the US.

Other Indian drug companies like Alkem Laboratories, Sun Pharmaceuticals, and Zydus Lifesciences are also involved in similar legal battles with Novo Nordisk.